NCT05974774View on ClinicalTrials.gov

Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors

PHASE3RecruitingINTERVENTIONAL
Enrollment

1,600

Participants

Timeline

Start Date

May 23, 2025

Primary Completion Date

May 23, 2035

Study Completion Date

June 1, 2039

Conditions
Prostate Cancer
Interventions
DRUG

iMAB

no treatment until significant PSA increase as per treating physician at which point patient restarts ADT (LHRH agonist or antagonist) + ARPI (abiraterone or enzalutamide or apalutamide or darolutamide). Once PSA \< 0.2 ng/mL, treatment stops again.

DRUG

cMAB

LHRH agonist or antagonist + ARPI (abiraterone or enzalutamide or apalutamide or darolutamide)

Trial Locations (9)

14076

RECRUITING

Centre Francois Baclesse, Caen

94805

RECRUITING

Gustave Roussy, Villejuif

Unknown

RECRUITING

University Hospitals Copenhagen - Rigshospitalet, Copenhagen

RECRUITING

Institut Daniel Hollard, Grenoble

RECRUITING

Clinique La Croix Du Sud, Quint-Fonsegrives

RECRUITING

CHU de Toulouse - Institut Claudius Regaud - IUCT oncopole, Toulouse

RECRUITING

Hospital Universitario San Carlos, Madrid

RECRUITING

Hospital Universitario Puerta De Hierro, Majadahonda

08041

RECRUITING

Hospital De La Santa Creu I Sant Pau, Barcelona

All Listed Sponsors
collaborator

Cancer Trials Ireland

NETWORK

collaborator

UNICANCER

OTHER

collaborator

Spanish Oncology Genito-Urinary Group

OTHER

lead

European Organisation for Research and Treatment of Cancer - EORTC

NETWORK